155 related articles for article (PubMed ID: 23449107)
1. Gene therapy for Canavan's disease takes a step forward.
Ahmed SS; Gao G
Mol Ther; 2013 Mar; 21(3):505-6. PubMed ID: 23449107
[No Abstract] [Full Text] [Related]
2. rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System.
Ahmed SS; Schattgen SA; Frakes AE; Sikoglu EM; Su Q; Li J; Hampton TG; Denninger AR; Kirschner DA; Kaspar B; Matalon R; Gao G
Mol Ther; 2016 Jun; 24(6):1030-1041. PubMed ID: 27039844
[TBL] [Abstract][Full Text] [Related]
3. Redirecting
Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
[TBL] [Abstract][Full Text] [Related]
4. Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease.
Velinov M; Zellers N; Styles J; Wisniewski K
Clin Genet; 2008 Mar; 73(3):288-9. PubMed ID: 18070137
[No Abstract] [Full Text] [Related]
5. Dietary treatment proposed for Canavan's disease.
Chen V
Lancet Neurol; 2005 May; 4(5):273. PubMed ID: 15861552
[No Abstract] [Full Text] [Related]
6. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.
Janson CG; Kolodny EH; Zeng BJ; Raghavan S; Pastores G; Torres P; Assadi M; McPhee S; Goldfarb O; Saslow B; Freese A; Wang DJ; Bilaniuk L; Shera D; Leone P
Ann Neurol; 2006 Feb; 59(2):428-31. PubMed ID: 16437572
[TBL] [Abstract][Full Text] [Related]
7. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.
Leone P; Janson CG; McPhee SJ; During MJ
Curr Opin Mol Ther; 1999 Aug; 1(4):487-92. PubMed ID: 11713764
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of Canavan's disease: from human to mouse.
Surendran S; Matalon KM; Tyring SK; Matalon R
J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138
[TBL] [Abstract][Full Text] [Related]
9. A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.
Ahmed SS; Li H; Cao C; Sikoglu EM; Denninger AR; Su Q; Eaton S; Liso Navarro AA; Xie J; Szucs S; Zhang H; Moore C; Kirschner DA; Seyfried TN; Flotte TR; Matalon R; Gao G
Mol Ther; 2013 Dec; 21(12):2136-47. PubMed ID: 23817205
[TBL] [Abstract][Full Text] [Related]
10. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in Canavan disease.
Matalon R; Michals-Matalon K
Adv Pediatr; 1999; 46():493-506. PubMed ID: 10645473
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus vectors for therapeutic gene transfer.
Stilwell JL; Samulski RJ
Biotechniques; 2003 Jan; 34(1):148-50, 152, 154 passim. PubMed ID: 12545552
[No Abstract] [Full Text] [Related]
14. Case 15-1998: elevated N-acetylaspartic acid activity in Canavan's disease.
Breslau J
N Engl J Med; 1998 Aug; 339(9):636. PubMed ID: 9722443
[No Abstract] [Full Text] [Related]
15. The impact of structural biology on neurobiology.
Viola RE
Proc Natl Acad Sci U S A; 2007 Jan; 104(2):399-400. PubMed ID: 17213329
[No Abstract] [Full Text] [Related]
16. Molecular basis of Canavan disease.
Matalon R; Michals-Matalon K
Eur J Paediatr Neurol; 1998; 2(2):69-76. PubMed ID: 10724099
[No Abstract] [Full Text] [Related]
17. White matter disease: Targeted aspartoacylase gene therapy reverts Canavan disease.
Starling S
Nat Rev Neurol; 2018 Jan; 14(1):4. PubMed ID: 29170500
[No Abstract] [Full Text] [Related]
18. Metabolic changes in the knockout mouse for Canavan's disease: implications for patients with Canavan's disease.
Surendran S; Matalon KM; Szucs S; Tyring SK; Matalon R
J Child Neurol; 2003 Sep; 18(9):611-5. PubMed ID: 14572139
[TBL] [Abstract][Full Text] [Related]
19. Current development of adeno-associated viral vectors.
Romano G
Drug News Perspect; 2005 Jun; 18(5):311-6. PubMed ID: 16193103
[TBL] [Abstract][Full Text] [Related]
20. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.
Baslow MH
J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
